Fever Clinical Guide

Assessment, tests, diagnosis and treatment. Built from Harrison’s Ch. 18–20, with 2024–2026 updates.

Assess a febrile patient

Red flags
Context

Fever and rash

Classify the dominant lesion and distribution first (Harrison Table 19-1), then use the history: immune status, drugs, travel, animals, ticks, vaccines.

Fever of unknown origin

Definition (all four)

  • Fever ≥38.3 °C (101 °F) on at least two occasions
  • Illness lasting ≥3 weeks
  • No known immunocompromise
  • Still unexplained after thorough history, examination and the obligatory tests below

Inflammation of unknown origin (IUO): same, but raised CRP/ESR on several occasions for ≥3 weeks without documented fever. Same workup.

Step 1. Obligatory investigations

First stop antibiotics and glucocorticoids if safe, and stop or replace drugs to exclude drug fever (fever persisting >72 h after stopping the drug makes it unlikely). Exclude thermometer manipulation.

Step 2. Look for potentially diagnostic clues (PDCs)

  • PDCs present: guided tests aimed at the suspected disease only. Screening tests have very low yield without PDCs.
  • PDCs absent or misleading: cryoglobulins and fundoscopy, then FDG-PET/CT (or labelled leukocyte scintigraphy or gallium scan if unavailable), especially when CRP/ESR is raised.
  • Repeat history and examination regularly; the diagnostic clue often appears late.

Step 3. After imaging

  • Abnormal scan: confirm with biopsy or culture.
  • Normal scan: repeat history and exam, PDC-driven invasive tests.
  • Still nothing: chest and abdominal CT; temporal artery biopsy if ≥55 years.
  • Stable: follow up for new PDCs, consider NSAID. Deteriorating: further tests or a therapeutic trial.
  • Consider a second opinion at an FUO expert centre.

Updated evidence

The 2024 EANM consensus on FDG-PET/CT in FUO/IUO reports a diagnostic yield or helpfulness of 50–60%, and places it early in the pathway. It outperforms conventional CT for reaching a final diagnosis. Glucocorticoids rapidly abolish pathological FDG uptake, so avoid them before the scan. A low-carbohydrate diet beforehand reduces physiological myocardial uptake when endocarditis is a concern.

Common causes (pooled studies)

RegionInfectionNon-infectious inflammatoryMalignancyNo diagnosis
Western Europe17%25%10%37%
Middle East66%15%7%8%
Asia42%20%13%18%

Medians. Tuberculosis is the leading infection in many non-Western cohorts. In the elderly, giant cell arteritis and polymyalgia rheumatica are most frequent. Lymphoma is the commonest neoplasm.

Treatment of FUO

  • Avoid empirical antibiotics, glucocorticoids or antituberculous drugs unless the patient is deteriorating, neutropenic or haemodynamically unstable.
  • Positive TST/IGRA, granulomatous disease, anergy or sarcoidosis unlikely: a trial of antituberculous therapy; reconsider if no response by 6 weeks.
  • Colchicine for suspected familial Mediterranean fever. NSAIDs for adult-onset Still’s disease.
  • Glucocorticoids for giant cell arteritis and polymyalgia rheumatica once lymphoma and infection are reasonably excluded.
  • Anakinra trial for suspected IL-1-mediated disease after later-stage tests.
  • Prognosis of unexplained FUO is favourable; mortality is driven by the underlying disease.

Treatment of fever

Decide whether to treat

Fever is a regulated response, not an illness. Antipyretics do not delay recovery from viral or bacterial infection, and are not contraindicated. In suspected bacterial infection, withholding them can help judge response to an antibiotic.

Treat actively when: pre-existing cardiac, pulmonary or CNS impairment (oxygen consumption rises about 13% per °C above 37), a history of febrile or non-febrile seizure in a child (Harrison), or marked symptoms such as headache, myalgia and arthralgia.

Agents

  • Paracetamol (acetaminophen): preferred first line. Equal to aspirin in fever reduction without platelet or gastric effects.
  • NSAIDs (ibuprofen): effective; caution with platelets, GI tract, kidneys.
  • Aspirin: avoid in children (Reye’s syndrome).
  • Parenteral or rectal forms if the patient cannot take oral drugs.
  • Glucocorticoids: antipyretic but mask disease; use only for specific diagnoses.

Dose by the product label and the patient’s weight, renal and hepatic function. Check local formulary.

Indian medicine brand reference

Verified product listings checked 2 November 2026. One sourced example per medicine (maximum five); brands are examples, not endorsements. Prices are indicative listed MRP for the stated pack, may vary by batch/location, and are not a treatment cost estimate. Where only the marketer is verified, it is labelled explicitly; check the pack for the manufacturing site.

Medicines mentioned in Treatment and FUO
MedicineIndian-market brand / strengthCompanyIndicative MRPSource
ParacetamolDolo 650
650 mg tablet
Micro Labs Ltd (marketer)₹32.28 / 15 tabletsProduct listing
Ibuprofen (NSAID)Brufen 400
400 mg tablet
Abbott (marketer)₹25.75 / 20 tabletsProduct listing
AspirinDisprin Regular
325 mg effervescent tablet
Reckitt Benckiser (India) Pvt Ltd₹7.07 / 10 tabletsProduct listing
Glucocorticoid: prednisoloneWysolone 5 DT
5 mg dispersible tablet
Pfizer Ltd (marketer)₹10.82 / 15 tabletsProduct listing
Colchicine (FUO: suspected FMF)Zycolchin
0.5 mg tablet
Zydus Cadila (marketer)₹35.04 / 10 tabletsProduct listing

Listed strengths identify products; they are not recommended doses. Oral adult tablets do not define a paediatric dose or substitute for rectal/injectable formulations. Prescribing must follow diagnosis, age/weight, organ function and the current product label.

  • Paracetamol: check all combination products to avoid duplicate dosing.
  • Ibuprofen / aspirin: avoid in suspected dengue or bleeding, dehydration or significant renal disease; check other NSAIDs and anticoagulants. Aspirin is not a routine childhood antipyretic.
  • Prednisolone and colchicine: prescription medicines for specific diagnoses, not routine treatment of undifferentiated fever. Colchicine has important renal/hepatic and drug-interaction constraints.
Specialist IL-1 medicines: Indian brand verification

Anakinra and canakinumab are mentioned in this guide. No routine Indian-market brand was verified in this review; no local price or Indian brand is asserted. Overseas products Kineret and Ilaris appear in specialist sourcing listings; these are not counted as Indian brands. Confirm local regulatory access, supply and cold chain with the specialist hospital pharmacy.

Anakinra sourcing reference · Canakinumab sourcing reference

Children under 5 (NICE NG143, last updated 2021)

  • Do not use antipyretics only to lower the temperature in an otherwise well child; they do not prevent febrile seizures.
  • Give paracetamol or ibuprofen if the child appears distressed.
  • If distress persists, switch to the other agent. Do not give both together; alternate only if distress recurs before the next dose.
  • Safety-net parents: seek help if the child looks worse, has a fit, develops a non-blanching rash, or fever lasts 5 days.

Hyperthermia and hyperpyrexia

  • Hyperthermia (heat stroke): set point unchanged, hot dry skin, does not respond to antipyretics. Cool physically; see Harrison Ch. 465.
  • Hyperpyrexia >41.5 °C: often CNS haemorrhage or severe infection.
  • Cooling blankets only together with oral antipyretics in fever. In CNS bleeding or trauma, lowering core temperature protects the brain.

Special settings

  • Anticytokine therapy (anti-TNF, IL-6, IL-17): fever is blunted. Low-grade fever warrants early, rigorous workup for TB, fungal and opportunistic infection.
  • Newborns, elderly, chronic liver or renal failure, steroid users: may have infection without fever.
  • Autoinflammatory disease: IL-1 blockade (anakinra, canakinumab) reduces fever.

Sources and cautions

  • Harrison’s Principles of Internal Medicine: Ch. 18 Fever, Ch. 19 Fever and Rash, Ch. 20 Fever of Unknown Origin (pages supplied).
  • Hess S et al. EANM consensus on [18F]FDG PET/CT in fever and inflammation of unknown origin. Eur J Nucl Med Mol Imaging, 2024.
  • NICE NG143: Fever in under 5s (published 2013, last updated 26 Nov 2021).

Source list supplied by the author, dated 19 Oct 2026. Newer local or national guidance may apply.

Decision-support and education tool for clinicians. It does not replace clinical judgement, local protocols or specialist advice. Outputs are not validated for individual patient care.